Consilium Wealth Advisory LLC Has $1.62 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Consilium Wealth Advisory LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 30.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,013 shares of the medical research company’s stock after purchasing an additional 1,179 shares during the quarter. Amgen makes up about 0.9% of Consilium Wealth Advisory LLC’s investment portfolio, making the stock its 26th largest position. Consilium Wealth Advisory LLC’s holdings in Amgen were worth $1,615,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Central Pacific Bank Trust Division bought a new position in Amgen during the 1st quarter worth approximately $414,000. Biechele Royce Advisors boosted its position in shares of Amgen by 1.4% during the first quarter. Biechele Royce Advisors now owns 67,075 shares of the medical research company’s stock worth $19,071,000 after purchasing an additional 950 shares in the last quarter. Hemenway Trust Co LLC grew its holdings in shares of Amgen by 18.5% in the 1st quarter. Hemenway Trust Co LLC now owns 1,259 shares of the medical research company’s stock valued at $358,000 after buying an additional 197 shares during the period. Cohen Capital Management Inc. increased its position in shares of Amgen by 5.1% in the 1st quarter. Cohen Capital Management Inc. now owns 2,096 shares of the medical research company’s stock valued at $596,000 after buying an additional 102 shares in the last quarter. Finally, Flossbach Von Storch AG acquired a new stake in Amgen during the 1st quarter worth $215,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.5 %

NASDAQ:AMGN traded up $1.65 during mid-day trading on Wednesday, hitting $320.94. 245,940 shares of the company’s stock were exchanged, compared to its average volume of 2,402,063. The company has a 50 day simple moving average of $324.12 and a 200-day simple moving average of $316.64. The firm has a market capitalization of $172.45 billion, a P/E ratio of 40.88, a PEG ratio of 2.81 and a beta of 0.60. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the business posted $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AMGN shares. Sanford C. Bernstein initiated coverage on Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.